VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
BGMBGM Group Ltd.
$0.32$2M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksBGMCash Flow

BGM Group Ltd. (BGM) Cash Flow Statement

8Y historyFree accessUpdated daily

Liquidity remains a primary concern as the absence of positive operating margins suggests the company is likely burning through its $9.8 million cash reserve to fund ongoing operations.

BGM Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
MetricSep'24Sep'23Sep'22Sep'21Sep'20Sep'19Sep'18Sep'17
Cash from Operations544.24K312.21K12.65M345.03K5.08M-580.2K4.44M2.68M
Operating CF Margin %2.17%0.67%19.51%0.6%10.15%-1.26%8.81%11.9%
Operating CF Growth %74.32%-97.53%3567.52%-93.2%974.88%-113.07%65.49%-
Net Income-1.52M-8.12M1.37M3.11M4.94M5.91M5.2M1.54M
Depreciation & Amortization1.24M1.14M1.22M1.2M1.17M1.19M1.25M1.24M
Stock-Based Compensation0020K00000
Deferred Taxes-406.85K203.54K189.84K-46.19K-86.5K48.66K15.8K57.51K
Other Non-Cash Items445.31K5.98M1.1M-246.34K-160.86K-30.78K205.47K71.87K
Working Capital Changes785.7K1.11M8.75M-3.67M-785.07K-7.69M-2.24M-227.6K
Change in Receivables1.33M-2.89M9.77M-157.5K-6.24M-1.46M-4.06M1.86M
Change in Inventory958.65K3.4M2.23M46.8K1.4M-3.49M2.81M-7.26M
Change in Payables378.98K-1.62M-805.44K2.02M613.34K-50.04K-824.54K2.72M
Cash from Investing983.42K-4.74M-3.26M-24.2M-375.59K-800.18K-1.39M-1.69M
Capital Expenditures-2.85M-1.85M-3.23M-3.49M-449.77K-616.39K-1.12M-1.52M
CapEx % of Revenue11.37%3.98%4.98%6.11%0.9%1.34%2.22%6.75%
Acquisitions0-28.36K0-706.66K0-133.55K00
Investments--------
Other Investing-1.02M-1.87M-26.68K-1.81K-8.8K-6350-7.13K
Cash from Financing-491.73K-2.92M-5.94M23.99M2.14M507.2K-3.12M1.25M
Debt Issued (Net)-491.73K-1.19M-5.94M123.7K2.14M872.51K-2.63M1.75M
Equity Issued (Net)0001000K0000
Dividends Paid0-1.79M0000-733.94K0
Share Repurchases00000000
Other Financing056.71K000-365.31K247.7K-493.14K
Net Change in Cash2.34M-7.5M2.37M740.24K7.27M-1.03M-246.08K2.31M
Free Cash Flow-3.39M-3.4M9.4M-3.15M0-1.2M3.32M1.15M
FCF Margin %-13.5%-7.32%14.49%-5.51%--2.6%6.59%5.11%
FCF Growth %0.43%-136.21%398.42%-100%-136.05%188.15%-
FCF per Share-0.47-0.471.30-0.46--0.170.470.16
FCF Conversion (FCF/Net Income)-0.38x-0.04x11.75x0.11x1.00x-0.11x0.86x1.90x
Interest Paid4.26K3.66K122.24K152.5K280.17K210.59K223.77K281.7K
Taxes Paid21.91K27.44K0820.97K275.61K1.11M658.41K48K

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetAdequate
Cash FlowDeteriorating
Top Statement Risk

Operational Cash Flow Uncertainty

Earnings Quality Remains Highly Uncertain

Given the absence of reported cash flow data in recent filings, the conversion efficiency between net income and operating cash flow remains entirely opaque, preventing a definitive assessment of whether the company's reported losses are being exacerbated by significant non-cash charges or actual cash burn.

The lack of transparency regarding cash conversion is particularly concerning given the firm's 45.99% revenue decline and negative operating margins. Investors should monitor future disclosures for a widening gap between accounting losses and cash outflows, which may indicate that the company is struggling to collect receivables from its provincial healthcare customers.

Free Cash Flow Generation Stalled

As indicated by the company's recent financial statements, the inability to maintain positive operating margins suggests that free cash flow generation is likely under severe pressure, potentially forcing the firm to rely on its $9.8 million cash reserve to fund ongoing operations and administrative overhead.

Without positive cash flow from operations, the company's ability to sustain its diverse product portfolio appears increasingly fragile. The current trajectory suggests that capital expenditures, even if minimal, may be consuming the remaining liquidity, leaving little room for strategic pivots or R&D investment.

Working Capital Efficiency Under Scrutiny

Based on the reported operational structure, the company's reliance on agricultural commodities like licorice root suggests that working capital cycles are likely volatile, with inventory build-ups potentially tying up critical liquidity during periods of declining demand for its pharmaceutical and fertilizer product lines.

The firm's dual-track model, spanning from API manufacturing to sausage casings, likely complicates inventory management and cash cycle optimization. Investors should be wary of potential inventory obsolescence, as the shelf life of biological assets could lead to significant write-downs that further impair the company's cash position.

Hidden Cash Flow Risks Obscured

The company's recent rebranding and shift in product focus may obscure underlying cash flow realities, as reported in financial disclosures that fail to provide a clear reconciliation between net income and the actual cash impact of its circular production model and waste management initiatives.

The reliance on repurposing pharmaceutical waste into fertilizers may be masking the true cost of production, potentially inflating gross margins in ways that do not translate to actual cash inflows. Analysts should investigate whether these operational efficiencies are truly cost-saving or merely a way to defer cash expenses that will eventually materialize on the balance sheet.

BGM — Frequently Asked Questions

Quick answers to the most common questions about buying BGM stock.

How much cash does BGM Group Ltd. (BGM) generate from operations?

BGM Group Ltd. (BGM) generated $0.5M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.

What is BGM Group Ltd.'s free cash flow?

BGM Group Ltd. (BGM) reported negative free cash flow of $3.4M in 2024, indicating capital requirements exceeded cash from operations.

What is BGM Group Ltd.'s capital expenditure (CapEx)?

BGM Group Ltd. (BGM) spent $2.9M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.